Cfra Analysts Give GlaxoSmithKline (GSK) a GBX 1,620 Price Target
Several other research firms have also recently weighed in on GSK. Goldman Sachs Group set a GBX 1,900 ($24.83) price objective on shares of GlaxoSmithKline and gave the stock a buy rating in a research report on Wednesday, October 31st. Societe Generale set a GBX 1,000 ($13.07) price objective on shares of GlaxoSmithKline and gave the stock a sell rating in a research report on Monday, September 10th. JPMorgan Chase & Co. set a GBX 1,600 ($20.91) price target on shares of GlaxoSmithKline and gave the stock a neutral rating in a report on Tuesday, September 18th. UBS Group restated a buy rating and issued a GBX 1,700 ($22.21) price target on shares of GlaxoSmithKline in a report on Thursday, September 27th. Finally, BNP Paribas set a GBX 1,750 ($22.87) price target on shares of GlaxoSmithKline and gave the stock a buy rating in a report on Tuesday, September 11th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of Hold and a consensus price target of GBX 1,512.99 ($19.77).
GSK opened at GBX 1,435 ($18.75) on Tuesday. GlaxoSmithKline has a twelve month low of GBX 1,235.20 ($16.14) and a twelve month high of GBX 1,724.50 ($22.53).
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Story: How Do Tariffs Affect Trade Balances?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.